JP2010539082A5 - - Google Patents

Download PDF

Info

Publication number
JP2010539082A5
JP2010539082A5 JP2010524063A JP2010524063A JP2010539082A5 JP 2010539082 A5 JP2010539082 A5 JP 2010539082A5 JP 2010524063 A JP2010524063 A JP 2010524063A JP 2010524063 A JP2010524063 A JP 2010524063A JP 2010539082 A5 JP2010539082 A5 JP 2010539082A5
Authority
JP
Japan
Prior art keywords
salt
complex according
cyclodextrin
complex
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010524063A
Other languages
English (en)
Japanese (ja)
Other versions
JP5474792B2 (ja
JP2010539082A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/056393 external-priority patent/WO2009035718A1/en
Publication of JP2010539082A publication Critical patent/JP2010539082A/ja
Publication of JP2010539082A5 publication Critical patent/JP2010539082A5/ja
Application granted granted Critical
Publication of JP5474792B2 publication Critical patent/JP5474792B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010524063A 2007-09-10 2008-03-10 亜鉛結合部分を含むキナゾリンベースegfrインヒビターの酒石酸塩またはその複合体 Expired - Fee Related JP5474792B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97105607P 2007-09-10 2007-09-10
US60/971,056 2007-09-10
PCT/US2008/056393 WO2009035718A1 (en) 2007-09-10 2008-03-10 Tartrate salts or complexes of quinazoline based egfr inhibitors containing a zinc binding moiety

Publications (3)

Publication Number Publication Date
JP2010539082A JP2010539082A (ja) 2010-12-16
JP2010539082A5 true JP2010539082A5 (cg-RX-API-DMAC7.html) 2011-03-24
JP5474792B2 JP5474792B2 (ja) 2014-04-16

Family

ID=40452375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010524063A Expired - Fee Related JP5474792B2 (ja) 2007-09-10 2008-03-10 亜鉛結合部分を含むキナゾリンベースegfrインヒビターの酒石酸塩またはその複合体

Country Status (7)

Country Link
US (3) US7846938B2 (cg-RX-API-DMAC7.html)
EP (1) EP2190287B1 (cg-RX-API-DMAC7.html)
JP (1) JP5474792B2 (cg-RX-API-DMAC7.html)
AU (1) AU2008299896B2 (cg-RX-API-DMAC7.html)
CA (1) CA2698944C (cg-RX-API-DMAC7.html)
ES (1) ES2526718T3 (cg-RX-API-DMAC7.html)
WO (1) WO2009035718A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101434164B1 (ko) 2006-09-11 2014-08-26 쿠리스 인코퍼레이션 아연 결합 부분을 함유한 퀴나졸린 계열 egfr 억제제
CN101570516B (zh) * 2009-04-14 2011-01-05 重庆威尔德·浩瑞医药化工有限公司 一种制备4-(3-氯-4-氟苯基胺基)-7-甲氧基-6-[3-(4-吗啉基)丙氧基]喹唑啉的方法
CN102452988B (zh) 2010-10-27 2016-01-27 中国科学院化学研究所 一种喹唑啉衍生物及其制备方法
CN103648500B (zh) 2011-03-17 2016-05-04 宾夕法尼亚大学理事会 双功能酶制钳型分子的方法和用途
US9295676B2 (en) 2011-03-17 2016-03-29 The Trustees Of The University Of Pennsylvania Mutation mimicking compounds that bind to the kinase domain of EGFR
US20140229256A1 (en) 2013-02-11 2014-08-14 Solutran Product substantiation using approved product list system and method
CN102276500A (zh) * 2011-05-05 2011-12-14 西安交通大学 水杨酰胺类抗肿瘤化合物及其合成方法和用途
KR20130047623A (ko) * 2011-10-28 2013-05-08 주식회사종근당 신규한 선택적인 히스톤탈아세틸화 효소 억제제로서의 하이드록사메이트 유도체 및 이를 포함하는 약제학적 조성물
WO2013159698A1 (zh) * 2012-04-26 2013-10-31 深圳信立泰药业股份有限公司 稠环喹唑啉羟肟酸类化合物及其作为抗肿瘤药物的应用
CN102898315B (zh) * 2012-11-05 2015-01-28 上海毕得医药科技有限公司 3-乙炔基-4-氟苯胺的制备方法
US10552861B2 (en) 2013-02-11 2020-02-04 Solutran, Inc. Dual redemption path with shared benefits system and method
RU2017105844A (ru) * 2014-08-08 2018-09-11 Форсайт Вижн4, Инк. Стабильные и растворимые составы ингибиторов рецепторных тирозинкиназ и способы их получения
CN105693630B (zh) * 2016-03-10 2018-02-16 田静 一种吉非替尼中间体的制备方法
WO2021044430A1 (en) * 2019-09-08 2021-03-11 Hadasit Medical Research Services And Development Ltd. Anti-fibrotic compounds and use thereof
US12100049B2 (en) 2020-06-05 2024-09-24 Soltran, LLC Filtered POS processing of services
EP4281449A1 (en) * 2021-01-20 2023-11-29 Lightox Limited Protected hdac (histone deacetylase) inhibitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
AU661533B2 (en) * 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
CA2124306C (en) * 1993-05-26 2004-04-06 Masami Muraoka Quinazolinone derivatives
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
JP4471404B2 (ja) * 1996-02-13 2010-06-02 アストラゼネカ ユーケイ リミテッド Vegfインヒビターとしてのキナゾリン誘導体
US6777217B1 (en) * 1996-03-26 2004-08-17 President And Fellows Of Harvard College Histone deacetylases, and uses related thereto
IL144745A0 (en) 1999-02-10 2002-06-30 Astrazeneca Ab Quinazoline derivatives as angiogenesis inhibitors
US7230000B1 (en) * 1999-10-27 2007-06-12 Cytokinetics, Incorporated Methods and compositions utilizing quinazolinones
UA74803C2 (uk) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
CA2439143A1 (en) 2001-02-26 2002-09-06 Mcgill University Combi-molecules having signal transduction inhibitory properties and dna damaging properties
AU2003257666A1 (en) * 2002-08-23 2004-03-11 Kirin Beer Kabushiki Kaisha COMPOUND HAVING TGFss INHIBITORY ACTIVITY AND MEDICINAL COMPOSITION CONTAINING THE SAME
US7250514B1 (en) * 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2514479A1 (en) * 2003-01-23 2004-08-05 T.K. Signal Ltd. Irreversible inhibitors of egf receptor tyrosine kinases and uses thereof
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
CA2540008A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
WO2005097134A2 (en) 2004-03-31 2005-10-20 The Scripps Research Institute Quinazoline based protein kinase inhibitors
EP2522397A1 (en) 2005-02-03 2012-11-14 TopoTarget UK Limited Combination therapies using HDAC inhibitors
CN101198314A (zh) * 2005-04-12 2008-06-11 伊兰制药国际有限公司 纳米微粒喹唑啉衍生物制剂
AU2006236557A1 (en) 2005-04-14 2006-10-26 Novartis Vaccines And Diagnostics Inc. 2-amino-quinazolin-5-ones as HSP90 inhibitors useful in treating proliferation diseases
ITMI20050729A1 (it) * 2005-04-22 2006-10-23 Endura Spa Nuova formulazione biologicamente attiva
EP2018366A4 (en) 2006-05-16 2010-08-04 Univ Mcgill HYBRID MOLECULES WITH MIXED VITAMIN D RECEPTOR AGONISM AND HISTONDEACETYLASE RESISTANT PROPERTIES
US20080221132A1 (en) * 2006-09-11 2008-09-11 Xiong Cai Multi-Functional Small Molecules as Anti-Proliferative Agents
KR101434164B1 (ko) * 2006-09-11 2014-08-26 쿠리스 인코퍼레이션 아연 결합 부분을 함유한 퀴나졸린 계열 egfr 억제제
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
CA2662587C (en) * 2006-09-11 2013-08-06 Curis, Inc. Quinazoline based egfr inhibitors
CN101573333B (zh) 2006-10-28 2013-06-12 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety

Similar Documents

Publication Publication Date Title
JP2010539082A5 (cg-RX-API-DMAC7.html)
JP2012153722A5 (cg-RX-API-DMAC7.html)
JP2011511073A5 (cg-RX-API-DMAC7.html)
TWI594986B (zh) Antineoplastic agent effect enhancer
JP2012505916A5 (cg-RX-API-DMAC7.html)
JP2010523476A5 (cg-RX-API-DMAC7.html)
JP2009533482A5 (cg-RX-API-DMAC7.html)
JP2017509586A5 (cg-RX-API-DMAC7.html)
JP2013537203A5 (cg-RX-API-DMAC7.html)
JP2014512356A5 (cg-RX-API-DMAC7.html)
JP2005500300A5 (cg-RX-API-DMAC7.html)
JP2010540555A5 (cg-RX-API-DMAC7.html)
JP2010526814A5 (cg-RX-API-DMAC7.html)
JP2017525730A5 (cg-RX-API-DMAC7.html)
JP2006503919A5 (cg-RX-API-DMAC7.html)
JP2015508103A5 (cg-RX-API-DMAC7.html)
JP2011509309A5 (cg-RX-API-DMAC7.html)
JP2010540556A5 (cg-RX-API-DMAC7.html)
JP2012526766A5 (cg-RX-API-DMAC7.html)
JP2012180344A5 (cg-RX-API-DMAC7.html)
JP2017530171A5 (cg-RX-API-DMAC7.html)
JP2014518544A5 (cg-RX-API-DMAC7.html)
JP2015512943A5 (cg-RX-API-DMAC7.html)
HRP20160545T1 (hr) Inhibitor fosfoinozitid 3-kinaze sa dijelom koji veže cink
JP2017524013A5 (cg-RX-API-DMAC7.html)